A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

A new stronger Ozempic is coming. Here's what to know — Nov 6th, 2024

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday. The Danish pharma giant fielded several questions from interested analysts about its next-gen GLP-1 medication CagriSema, regarding its efficacy, safety, and supply chain. ...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

Novo Nordisk Slumps On Tightened Outlook As Wegovy Beats, But Ozempic Lags — Nov 6th, 2024

Novo Nordisk stock fell Wednesday after the drugmaker's weight-loss drug beat forecasts, but Ozempic sales missed. Continue reading View comments...

Novo Nordisk Slumps On Tightened Outlook As Wegovy Beats, But Ozempic Lags — Nov 6th, 2024

Novo Nordisk stock fell Wednesday after the drugmaker's weight-loss drug beat forecasts, but Ozempic sales missed. Continue reading View comments...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

A new stronger Ozempic is coming. Here's what to know — Nov 6th, 2024

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday. The Danish pharma giant fielded several questions from interested analysts about its next-gen GLP-1 medication CagriSema, regarding its efficacy, safety, and supply chain. ...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

A new stronger Ozempic is coming. Here's what to know — Nov 6th, 2024

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday. The Danish pharma giant fielded several questions from interested analysts about its next-gen GLP-1 medication CagriSema, regarding its efficacy, safety, and supply chain. ...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

What can't Ozempic and other weight loss drugs cure? — Nov 6th, 2024

It seems like every day a new study emerges linking Ozempic and similar drugs to new health benefits. Ozempic is part of a drug class known as GLP-1 medications, which mimic gut hormones that help regulate blood sugar and suppress appetite. These drugs have become popular for their effecti...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...

The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock. — Nov 21st, 2024

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine so...

What can't Ozempic and other weight loss drugs cure? — Nov 6th, 2024

It seems like every day a new study emerges linking Ozempic and similar drugs to new health benefits. Ozempic is part of a drug class known as GLP-1 medications, which mimic gut hormones that help regulate blood sugar and suppress appetite. These drugs have become popular for their effecti...

A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup — Nov 8th, 2024

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter, surpassing Wall Street expectations. The millennial...

Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop — Nov 21st, 2024

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come. Continue reading View comments...